A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors - Wikidata - wikimedia - TriplyDB

A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors

A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors

http://www.wikidata.org/entity/Q34334959

about

Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications Preclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and Recommendations Sunitinib: the antiangiogenic effects and beyond Evolving Therapies and FAK Inhibitors for the Treatment of Cancer A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.Regorafenib: from bench to bedside in colorectal cancer.The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors.5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma.Targeting angiogenesis in metastatic breast cancer Simultaneous delivery of cytotoxic and biologic therapeutics using nanophotoactivatable liposomes enhances treatment efficacy in a mouse model of pancreatic cancer.The potential of sunitinib as a therapy in ovarian cancer.Drug interactions with sunitinib.Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literature.Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy.Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor mo

P2860

Q26764899-4C50ADD7-1442-4C12-9DE6-AE12CF97973B Q26767798-66FC9B09-A054-433B-A420-D0CCED2A1835 Q28066499-FDFA8A76-E401-4110-BE10-99AEC4F9AC53 Q28972291-96CD2D06-93D1-4C46-A300-54871DF842C2 Q33274982-EBCA8EEC-E2E3-422F-91C2-04A0F942F957 Q33633431-A338DAE4-5013-4267-9501-5D8C4964B258 Q34343524-D5FBC59F-82B7-4DEA-B5B0-E7A50E8CD664 Q34725749-D6BD2F46-B979-4956-8B89-F9D0BC366D59 Q36084341-2C4C2760-D987-4631-8FF6-43AE60280360 Q36182795-89C634AA-F518-474A-89CA-976DCCBC6A77 Q36505652-E00D8DCD-BC8D-4508-94D1-67EBAE1AC973 Q38144166-00F9EC14-8227-412F-A73D-4A3C7848EE10 Q38176853-8C8ED936-2ED9-4A95-A044-6BB0D3F91921 Q38322346-8FC3EC26-6E70-422A-8C79-B501AE605649 Q38334611-F37E4AF8-40D7-4122-91F9-45F2694FCA66 Q39995898-E628325A-0C2F-42A4-883B-9C266F75769D Q40126912-673DD97B-15D7-423A-88BA-0CA8A213E3F4 Q43841175-6E3A4CEB-733A-4409-8823-B03F099D104E Q49886531-FBAADA8B-A187-4321-BC5B-2168B8F202A0 Q54526385-C6F9C0E7-7E90-4196-B2D2-791764841C82

P2860

A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors

http://www.wikidata.org/entity/Q34334959

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors

@ast

A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors

@en

A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors

@nl

type

label

A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors

@ast

A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors

@en

A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors

@nl

prefLabel

A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors

@ast

A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors

@en

A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors

@nl

P1433

Q34334959-B14D464F-FE0E-452E-8581-A30CBDDE6AF6

P1476

Q34334959-C2EBFE23-27E1-4D1A-A98E-516B302DD786

P2093

Q34334959-05066DE0-45A9-4378-9FD2-B761D5D0229A

Q34334959-417A75C5-A535-4426-B03C-0A92ECD0D5E2

Q34334959-442CE5FD-5169-4ABD-AAE9-26A13779C6D7

Q34334959-5C710349-D74A-47E1-8BDB-216E2FF164CA

Q34334959-85A6DC73-83D6-4584-BBF4-0FB25E0A52AC

Q34334959-8C4B3AA4-1C50-482B-9C7F-469FB767A8DB

Q34334959-B748FBA6-0D4A-41CC-8E17-D55B9162570E

Q34334959-C0ABC7D2-D87C-460D-9EC9-98B008BCC184

Q34334959-E0744437-8112-43F4-B067-8DA934CAA899

Q34334959-EB688113-B2D4-498A-98CC-F1524EC7E33C

P2860

Q34334959-0069797E-9140-481F-8B13-1847849C0333

Q34334959-06EFC567-7C78-4FA4-88E4-96A86E888B09

Q34334959-158F33CF-4EF8-4F7C-A440-CAF217613BFC

Q34334959-161264AE-32B2-4AE2-91EA-0E1D1F79249C

Q34334959-1CB58A65-E9CE-4BE5-B834-927245158A4D

Q34334959-25863EA0-0876-417A-B6AB-53B08E2CB648

Q34334959-33B254E9-E350-4182-9B5D-FA7FE85A7861

Q34334959-3AAEE6FF-9EED-4B80-A078-7E8D4EAE9DB6

Q34334959-4197D839-436D-40F9-BB5C-7EDEAACEBFD7

Q34334959-43F0AD88-3B92-4374-926F-90C328D9BA3E

P304

Q34334959-F8289F2B-ED07-436C-B91C-5127FB688152

P31

Q34334959-5F2EB7C4-FC58-4622-B417-1276464E9F8A

P356

Q34334959-F4ADEDA1-7B47-4838-A879-15EDE1FEEF2D

P407

Q34334959-9A888B62-5E11-48E6-B725-E7D88486CF2B

P433

Q34334959-16749579-1A11-4E27-B077-99A73DC5C6DE

P478

Q34334959-785FFDA2-AF62-42CC-BCA3-F67D93331A96

P577

Q34334959-0AF4E92B-E6A6-4072-9617-F42FC0D98B5C

P698

Q34334959-C0F5EC7D-7E15-488D-82F8-EE54A33AE5D0

P932

Q34334959-2BE1AA63-954D-412D-A518-5C44B7A9022E

P356

JCO.2009.26.9696

P1433

Journal of Clinical Oncology

P1476

A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors

@en

P2093

Akintunde Bello

http://www.w3.org/2001/XMLSchema#string

Christopher J Sweeney

http://www.w3.org/2001/XMLSchema#string

Claire F Verschraegen

http://www.w3.org/2001/XMLSchema#string

E Gabriela Chiorean

http://www.w3.org/2001/XMLSchema#string

Fa Chyi Lee

http://www.w3.org/2001/XMLSchema#string

Howard A Burris

http://www.w3.org/2001/XMLSchema#string

Katherine F Liau

http://www.w3.org/2001/XMLSchema#string

Lesley Tye

http://www.w3.org/2001/XMLSchema#string

Melanie Royce

http://www.w3.org/2001/XMLSchema#string

Richard Chao

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity.

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Clinical pharmacokinetics of capecitabine.

P304

4513-4520

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.26.9696

http://www.w3.org/2001/XMLSchema#string

P407

P433

29

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20837944

http://www.w3.org/2001/XMLSchema#string

P932

2988641

http://www.w3.org/2001/XMLSchema#string